Patents by Inventor James Cardia

James Cardia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNA INTERFERENCE IN SKIN INDICATIONS
    Publication number: 20140315974
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
    Type: Application
    Filed: December 12, 2013
    Publication date: October 23, 2014
    Applicant: RXI PHARMACEUTICALS CORPORATION
    Inventors: ANASTASIA KHVOROVA, WILLIAM SALOMON, JOANNE KAMENS, DMITRY SAMARSKY, TOD M. WOOLF, PAMELA A. PAVCO, JAMES CARDIA
  • Reduced size self-delivering RNAi compounds
    Patent number: 8796443
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: August 5, 2014
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
    Publication number: 20140113950
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.
    Type: Application
    Filed: March 24, 2011
    Publication date: April 24, 2014
    Applicant: RXI PHARMACEUTICALS CORPORATION
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
  • RNA interference in skin indications
    Patent number: 8664189
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: March 4, 2014
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, James Cardia
  • REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS
    Publication number: 20130131141
    Abstract: The present invention relates to methods for in vivo administration of sd-rxRNA molecules.
    Type: Application
    Filed: March 24, 2011
    Publication date: May 23, 2013
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • RNA INTERFERENCE IN OCULAR INDICATIONS
    Publication number: 20130131142
    Abstract: The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.
    Type: Application
    Filed: March 24, 2011
    Publication date: May 23, 2013
    Inventors: Lyn Libertine, Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS
    Publication number: 20120040459
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.
    Type: Application
    Filed: September 22, 2009
    Publication date: February 16, 2012
    Applicant: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS
    Publication number: 20110263680
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing. The RNAi constructs may be, for instance, miRNA constructs that are miRNA modulators.
    Type: Application
    Filed: March 23, 2011
    Publication date: October 27, 2011
    Applicant: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia